The New England Journal of Medicine

Devanand, Nilesh Anand; de Meirsman, Robin

doi: 10.1056/NEJMicm2413940pmid: 40126511

Red Urine after Administration of HydroxocobalaminA 40-year-old man who was being treated in the ICU after inhalation of car exhaust in a suicide attempt was noted to have red urine.

Rubin, Eric J.; Baden, Lindsey R.; Kawaoka, Yoshihiro; Morrissey, Stephen

doi: 10.1056/NEJMe2502267pmid: 40043251

NEJM Outbreaks Update — H5N1In this audio interview for NEJM Outbreaks Update, Editor-in-Chief Eric Rubin and Deputy Editor Lindsey Baden speak with Yoshihiro Kawaoka.

doi: 10.1056/NEJMc2501311pmid: 40138567

To the Editor: In the final, 10-year outcomes of the CheckMate 067 trial reported by Wolchok et al. (Jan. 2 issue),1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary of the fact that this combination was not designed to be compared with nivolumab alone, and the difference in survival between the two trial groups was not significant. This finding is noteworthy, given that nivolumab alone had an incidence of adverse events of only 25% (as compared with 63% in the combination group). Among . . .

doi: 10.1056/NEJMc2501201pmid: 40138570

To the Editor: Inhibition of factor XI or activated factor XI (XIa) should provide protection against stroke with a low risk of bleeding, given that the incidence of bleeding or adverse cardiovascular events is low among persons with intrinsic factor XI deficiency. In the OCEANIC-AF trial reported by Piccini et al. (Jan. 2 issue),1 patients who received asundexian at a once-daily dose of 50 mg had a lower risk of bleeding than those who received apixaban; however, asundexian was associated with a higher risk of stroke or systemic thromboembolism than apixaban (hazard ratio, 3.79; 95% confidence interval, 2.46 to 5.83), . . .

Rubin, Eric J.; Leopold, Jane; Morrissey, Stephen

doi: 10.1056/NEJMe2414476pmid: 39555802

In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions. . . .

Abu Fraiha, Yasmeen; Ahmed, Abdalrahman; Alon, Noam; Halperin, Avner

doi: 10.1056/NEJMp2416553pmid: 40126476

Health Care Bridges in Gaza and BeyondEven as hospitals in Gaza were turned into battlefields, some Palestinian–Israeli health care programs bridged the deep divides and continued to build trust between the populations in conflict.

Mazoyer, Heloise; Bachmeyer, Claude

doi: 10.1056/NEJMicm2411990pmid: 40126512

Sézary SyndromeA 27-year-old man presented with a 6-month history of an itchy rash. Confluent, hyperpigmented plaques across the torso and upper arms and axillary and inguinal lymphadenopathy were noted on examination.

doi: 10.1056/NEJMtwj250327pmid: N/A

Gurney, Jason

doi: 10.1056/NEJMp2414167pmid: 40126489

The Definition of FailureWhen his mother is diagnosed with what medicine calls “heart failure,” an epidemiologist identifies harmful flaws in both the term and communication with patients and families.

Fuse Brown, Erin C.; Wouters, Olivier J.; Mehrotra, Ateev

doi: 10.1056/NEJMp2500379pmid: 40126465

Pharmaceutical–Telehealth PartnershipsSome pharmaceutical companies have launched platforms that direct users to websites run by telehealth companies, where clinicians are available to prescribe drugs. Such arrangements have prompted concerns.